About Juno therapeutics, inc.
Juno Therapeutics, Inc. is a biopharmaceutical company that specializes in developing innovative cancer treatments. The company was founded in 2013 and is headquartered in Seattle, Washington. Juno Therapeutics has a mission to revolutionize the treatment of cancer by using cutting-edge technology to create personalized therapies for patients.
Juno Therapeutics is committed to discovering and developing new treatments for cancer patients who have limited options available to them. The company's approach involves using genetically engineered T cells, which are immune cells that can be programmed to recognize and attack cancer cells.
One of Juno Therapeutics' most promising products is called JCAR017, which is a CAR-T cell therapy designed to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This type of lymphoma is particularly difficult to treat because it often does not respond well to traditional chemotherapy or radiation therapy.
JCAR017 works by taking T cells from the patient's own body and engineering them with a chimeric antigen receptor (CAR) that recognizes CD19, a protein found on the surface of B cells. Once these CAR-T cells are infused back into the patient's body, they seek out and destroy cancerous B cells.
In clinical trials, JCAR017 has shown impressive results with high response rates and durable remissions in patients with relapsed or refractory DLBCL. Juno Therapeutics plans to continue developing this therapy for other types of blood cancers as well.
Another product in Juno Therapeutics' pipeline is JCAR014, which targets CD19-positive acute lymphoblastic leukemia (ALL). This product has also shown promising results in early-stage clinical trials.
In addition to its CAR-T cell therapies, Juno Therapeutics also has several other programs focused on developing new treatments for solid tumors such as lung cancer and ovarian cancer. These programs involve using different types of immune cells such as natural killer (NK) cells and gamma delta T cells.
Juno Therapeutics has partnered with several other companies including Celgene Corporation and Editas Medicine Inc., which allows them access to additional resources for research and development efforts.
Overall, Juno Therapeutics' commitment towards discovering innovative medicines for serious diseases like cancer makes it an important player within the biopharmaceutical industry. With its cutting-edge technology platform focused on personalized therapies tailored specifically towards individual patients needs; it stands poised at the forefront of medical innovation today!